LB Pharmaceuticals CFO reports no LBRX holdings

LB PHARMACEUTICALS INC (ticker LBRX) reports that its Chief Financial Officer, Joseph M. Miller, has filed an initial statement of beneficial ownership on Form 3.

Rhea-AI Filing Summary

LB PHARMACEUTICALS INC (ticker LBRX) reports that its Chief Financial Officer, Joseph M. Miller, has filed an initial statement of beneficial ownership on Form 3. The filing shows no reportable equity holdings or transactions for him at this time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 3 filing mean for LBRX?

The filing records that LB PHARMACEUTICALS INC’s Chief Financial Officer, Joseph M. Miller, has submitted his initial beneficial ownership report on Form 3, and it currently shows no reportable equity holdings or transactions.

Did the LBRX Chief Financial Officer buy or sell any shares in this Form 3?

No. The Form 3 for LB PHARMACEUTICALS INC’s Chief Financial Officer reports no transactions, with buy, sell, acquire, dispose, and other transaction counts all at zero.

Does the LBRX Form 3 show any stock or options owned by the CFO?

No. The Form 3 summary indicates no reported holdings, with holding entries and derivative positions both at zero, meaning no reportable common stock or derivatives are listed in this filing.

Is there any Rule 10b5-1 trading plan disclosed in this LBRX Form 3?

No. The document-level indicator for a Rule 10b5-1 plan is null, and there are no footnote disclosures tying any transactions to a trading plan, consistent with the absence of any reported trades.

Who is the reporting person in this LBRX Form 3?

The reporting person is Joseph M. Miller, identified as an officer of LB PHARMACEUTICALS INC with the title Chief Financial Officer. He is not identified as a director or ten percent owner in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:16 PM Accepted by SEC EDGAR 09/14/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Miller Joseph M

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NEW YORK 10119

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/02/2026

3. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Marc Panoff, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)